DYNAMITE is a research project focused on tackling chemoresistance in high-grade serous carcinoma (HGSC), the most common and deadly ovarian cancer subtype. Most HGSC patients face recurrence and resistance to chemotherapy, resulting in low survival rates. This resistance is not solely due to genetic mutations but also involves changes in gene regulation driven by specific proteins called transcription factors (TFs). DYNAMITE uses advanced single-cell technologies to identify the pathways and TFs linked to chemoresistance. These findings are then tested in patient-derived 3D cancer models to screen potential combination therapies. Ultimately, DYNAMITE aims to identify personalized treatment targets, paving the way for new therapies tailored to each patient's unique tumor profile.

2025

2028